8-K: Exact Sciences Reports Record Q3 Revenue, Raises 2025 Outlook

Exact Sciences announced record third-quarter 2025 revenue of $851 million, a 20% increase, and raised its full-year 2025 guidance, driven by strong performance in its Screening and Precision Oncology segments and the launch of its Cancerguard test.

Summary

• Delivered record total third quarter revenue of $851 million, an increase of 20% on a reported and core revenue basis, compared to $709 million for the same period of 2024.
• Screening revenue reached $666 million, an increase of 22% year-over-year.
• Precision Oncology revenue was $184 million, an increase of 13% year-over-year.
• Net loss improved to $20 million, or $0.10 per share, an improvement of $19 million and $0.10 per share, respectively, compared to a net loss of $38 million, or $0.21 per share, in Q3 2024.
• Adjusted EBITDA was $135 million, an increase of $37 million or 37%, and adjusted EBITDA margin was 16%, an increase of 200 basis points.
• Generated record operating cash flow of $220 million and free cash flow of $190 million, representing increases of 59% and 69%, respectively.
• Cash, cash equivalents, and marketable securities totaled $1.00 billion at the end of the quarter.
• Raised full-year 2025 total revenue guidance midpoint by $77.5 million to a new range of $3.220 $3.235 billion.
• Raised full-year 2025 adjusted EBITDA guidance midpoint by $10 million to a new range of $470 $480 million.
• Launched Cancerguard, the company's multi-cancer early detection test, for patients in the United States in September 2025.
• Announced an agreement with Quest Diagnostics to enable Cancerguard blood collection at approximately 7,000 patient access sites across the U.S.

Sentiment

Score: 8

Explanation: The company reported record revenue, significantly improved profitability metrics (reduced net loss, increased adjusted EBITDA), and generated strong cash flow. The upward revision of full-year guidance and the successful launch of a new multi-cancer early detection test (Cancerguard) indicate strong operational momentum and positive strategic execution, despite still reporting a net loss.

Positives

• Record total third-quarter revenue of $851 million, representing a 20% increase year-over-year.
• Strong growth in Screening revenue (22% increase to $666 million) and Precision Oncology revenue (13% increase to $184 million).
• Significant improvement in net loss, reducing by $19 million to $20 million, and net loss per share improving by $0.10 to $0.10.
• Adjusted EBITDA increased by 37% to $135 million, with the adjusted EBITDA margin expanding by 200 basis points to 16%.
• Generated record cash from operations ($220 million, up 59%) and free cash flow ($190 million, up 69%).
• Raised full-year 2025 total revenue guidance midpoint by $77.5 million, indicating increased confidence in future sales.
• Raised full-year 2025 adjusted EBITDA guidance midpoint by $10 million, reflecting improved profitability expectations.
• Successful launch of Cancerguard, a multi-cancer early detection test, expanding the product portfolio into a high-growth area.
• Strategic agreement with Quest Diagnostics significantly enhances patient access to Cancerguard blood collection services.

Negatives

• Reported a net loss of $20 million for the quarter, despite significant improvements.
• Operating expenses remain substantial, with total operating expenses at $609.474 million for the quarter.
• Interest expense, net, increased to $9.789 million for the quarter, up from $9.607 million in the prior year period.

Risks

• Ability to successfully develop and commercialize new products and services and assess potential market opportunities.
• Ability to successfully and profitably market products and services, and their acceptance by patients and healthcare providers.
• Reliance upon certain suppliers for critical components or services.
• Ability to retain and hire key personnel essential for operations and innovation.
• Approval and maintenance of adequate reimbursement rates for products and services within and outside the U.S.
• The amount and nature of competition for products and services in the diagnostics market.
• Effects of any judicial, executive or legislative action affecting the company or the healthcare system, including government shutdowns and changes in policies.
• Recommendations, guidelines and quality metrics issued by various organizations regarding cancer screening or products and services.
• Ability to obtain and maintain regulatory approvals and comply with applicable regulations for diagnostic tests.
• Ability to protect and enforce intellectual property rights against infringement.
• Success in establishing and maintaining collaborative, licensing, and supplier arrangements.
• Risks that the results of future validation studies and clinical trials may differ materially from previously completed studies and trials.
• Ability to manage an international business and expectations regarding international expansion and opportunities.
• Potential effects of changing macroeconomic conditions and geopolitical conflict on business operations and financial performance.
• Possibility that the anticipated benefits from business acquisitions or collaborative/licensing arrangements will not be realized in full or at all or may take longer than expected.
• Possibility that the anticipated benefits from restructuring and cost reduction initiatives will not be realized in full or at all or may take longer than expected.
• Outcome of any potential litigation or legal proceeding.
• Ability to raise the capital necessary to support operations or meet payment obligations under indebtedness.

Future Outlook

Exact Sciences raised its full-year 2025 revenue guidance to a range of $3.220 $3.235 billion, up from the prior guidance of $3.130 $3.170 billion. Adjusted EBITDA guidance for the full year was also increased to $470 $480 million, up from $455 $475 million previously. The company anticipates continued growth fueled by its Cologuard and Oncotype DX brands and the recent launch of Cancerguard.

Management Comments

• "Exact Sciences continues to advance our mission to prevent cancer and detect it earlier through a relentless focus on patients."
• "Our third quarter results reflect the power of our patient-centric platform and our trusted brands, Cologuard and Oncotype DX."
• "The momentum we are building is fueling growth, advancing innovative new tests like Cancerguard, and strengthening our financial performance."

Industry Context

The launch of Cancerguard positions Exact Sciences as a significant player in the emerging multi-cancer early detection (MCED) market, a rapidly evolving field aimed at detecting various cancers from a single blood draw. This aligns with a broader industry trend towards less invasive, earlier detection methods, which could revolutionize cancer screening beyond traditional single-cancer tests like Cologuard. The partnership with Quest Diagnostics for blood collection is a strategic move to leverage existing infrastructure, a common approach in the diagnostics industry to scale new test adoption.

Comparison to Industry Standards

• The launch of Cancerguard places Exact Sciences in direct competition with other companies developing multi-cancer early detection (MCED) tests, such as Grail (Galleri) and Guardant Health (Shield). Cancerguard's approach of analyzing multiple biomarker classes and being supported by robust test-development studies like DETECT-A and ASCEND 2, involving over 20,000 participants, is comparable to the extensive clinical validation efforts undertaken by its peers in this nascent but high-potential market.
• Cologuard, as a non-invasive stool-based colorectal cancer screening test, remains a market leader and is included in national screening guidelines, setting a high standard for accessibility and clinical utility in its category. Its 20 million uses since 2014 demonstrate significant market penetration compared to other non-invasive CRC screening options.
• Oncotype DX Breast Recurrence Score test is recognized as the standard of care and included in all major breast cancer treatment guidelines, indicating its strong position and clinical acceptance relative to other genomic tests in breast cancer.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased guidance, and strategic product launches, potentially leading to increased share value.
• Patients: Enhanced access to early cancer detection and diagnostic tests through Cologuard, Oncotype DX, and the newly launched Cancerguard, potentially improving health outcomes.
• Healthcare Providers: New tools like Cancerguard and Cologuard Plus offer more options for screening and diagnosis, aiding in patient care decisions.
• Employees: Restructuring and business transformation initiatives mentioned in non-GAAP adjustments indicate some employee termination costs, suggesting potential impact on certain support functions globally.

Next Steps

• Company management will host a conference call and webcast on November 3, 2025, at 5 p.m. ET to discuss third-quarter 2025 results.
• Continued commercialization and patient access expansion for Cancerguard, including leveraging the Quest Diagnostics agreement.
• Ongoing development and potential regulatory approvals for pipeline products like Oncodetect and Cancerguard (which is currently a laboratory-developed test).
• Execution of the multi-year productivity plan, including restructuring and business transformation initiatives.

Key Dates

Recommendation

The company delivered exceptional third-quarter results, marked by record revenue growth across both Screening and Precision Oncology segments, significant improvement in net loss, and robust adjusted EBITDA expansion. The generation of record operating and free cash flow demonstrates strong financial health. Furthermore, the upward revision of full-year guidance signals management's confidence in sustained performance. The successful launch of Cancerguard, a multi-cancer early detection test, and the strategic partnership with Quest Diagnostics position the company favorably in a high-growth market, indicating strong future potential and strategic execution. These factors collectively present a compelling investment opportunity.

Keywords

Exact Sciences, EXAS, Cancer Screening, Diagnostic Tests, Cologuard, Oncotype DX, Cancerguard, Multi-Cancer Early Detection, Precision Oncology, Financial Results, Q3 2025, Revenue Growth, Adjusted EBITDA, Cash Flow, Biotechnology, Healthcare, Genomic Testing, Early Cancer Detection